Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nyse  >  Bristol-Myers Squibb Company    BMY

News SummaryMost relevantAll newsSector newsTweets
The feature you requested does not exist. However, we suggest the following feature:

Pfizer : SMi Releases Agenda for Their 10th Annual Social Media in Pharma Conference

share with twitter share with LinkedIn share with facebook
share via e-mail
09/20/2017 | 09:01am CEST

London, United Kingdom, September 20, 2017 --(PR.com)-- SMi's Social Media in Pharma is now in its 10th annual year, network and learn from the most senior industry thought leaders in pharma and social media such as Pfizer, Janssen, Roche Diabeties Care, CREATION, Bristol-Myers Squibb, GSK, DRG Digital, IBM and more.

Social media is the perfect channel for pharmaceutical companies to educate, market, listen and connect with customers, patients and physicians. Explore strategies in patient engagement in order to create a powerful social media strategy, digital marketing techniques, approaches to content creation and big data and wearable technologies.

How the pharmaceutical industry utilize social media is particularly complex as regulators such as the FDA have not yet written the rules about how pharmaceuticals can engage with potential customers and patients. www.social-media-pharma.com/prc

Featured Highlights:

- Hear how Janssen create powerful pharmaceutical social media strategies enabling patient engagement.

- Learn how to build integrated, impactful social media strategies with Pfizer.

- Discuss the potential of wearable technologies creating behavioural changes for patients with UCB.

- Discover with GSK how to make your social media content less “promotional” and more about storytelling.

- Examine how Bristol Myers-Squibb create an excellent digital strategy whilst engaging patients.

Plus, don’t miss:

The opening address will be presented by Aslihan Unal, Digital Strategy Group Manager, from Janssen. Gain a deeper insight into creating powerful pharmaceutical social media strategies enabling patient engagement. This will examine building an effective social media strategy, the lessons learned and pitfalls on navigating today's social landscape, and how pharma social media can stay relevant and evolve into this evolving industry.

Not only this, put learnings into practise with an interactive half-day post-conference workshop! Get involved and learn from Timos Papagatsias, CEO and Elvira Dragas, Partner, from LucidQuest who will focus on how stakeholders can combine the latest advancements in Social Media / Social Networking and Strategic Competitive Intelligence in order to uncover opportunities and threats for their companies and brands.

Check out the agenda + full speaker line-up: www.social-media-pharma.com/prc

For those looking to attend there is currently a £400 early-bird saving.

SMi Presents the Launch of…
Social Media in the Pharmaceutical Industry
Date: 22nd – 23rd January 2017
Location: Kensington, London
Website: www.social-media-pharma.com/prc

Contact Information:

For all media inquiries contact Pavan Solanki on Tel: +44 (0)20 7827 6048 / Email: [email protected]

About SMi Group:

Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world's most forward-thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at http://www.smi-online.co.uk

Contact Information:
SMi Group
Pav Solanki
+44 (0) 20 7827 6048
Contact via Email

Read the full story here: http://www.pr.com/press-release/730203

Press Release Distributed by PR.com

09/20 PFIZER : SMi Releases Agenda for Their 10th Annual Social Media in Pharma Confer..
09/18 PFIZER : Have you seen the agenda for the 10th Annual Social Media in Pharma?
09/15 ASTRAZENECA : Designed to Treat Type 2 Diabetes, Dapagliflozin Provides Signific..
09/15 Halozyme signs mammoth drug partnerships
09/14 BRISTOL MYERS SQUIBB : Trademark Application for "DESQUAM-E" Filed by Bristol-My..
09/14 BRISTOL MYERS SQUIBB : to Take Part in Morgan Stanley Global Health Care Confere..
09/14 BRISTOL MYERS SQUIBB : Completes Previously Announced Acquisition of IFM Therape..
09/14 BRISTOL MYERS SQUIBB : Reports Outline Pharmacology and Experimental Therapeutic..
09/14 BRISTOL MYERS SQUIBB : Findings from Bristol-Myers Squibb Reveals New Findings o..
09/14 BRISTOL MYERS SQUIBB : Investigators at Bristol-Myers Squibb Report Findings in ..
More news
News from SeekingAlpha
09/20 Novartis' Opdivo available to a number of lung cancer patients in England thr..
09/18 THE IM-CAPITAL STRENGTH 20-STOCK UNI : Update September 2017
09/17 3 THINGS IN BIOTECH YOU SHOULD LEARN : September 17, 2017
09/16 3 THINGS IN BIOTECH YOU SHOULD LEARN : September 16, 2017
09/14 Halozyme out-licenses ENHANZE to Roche and Bristol Myers for up to $455M; rai..
Financials ($)
Sales 2017 20 505 M
EBIT 2017 5 528 M
Net income 2017 4 570 M
Debt 2017 771 M
Yield 2017 2,51%
P/E ratio 2017 22,71
P/E ratio 2018 20,75
EV / Sales 2017 5,07x
EV / Sales 2018 4,89x
Capitalization 103 B
Duration : Period :
Bristol-Myers Squibb Compa Technical Analysis Chart | BMY | US1101221083 | 4-Traders
Technical analysis trends BRISTOL-MYERS SQUIBB COMPA
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 23
Average target price 58,3 $
Spread / Average Target -7,4%
EPS Revisions
Giovanni Caforio Chairman & Chief Executive Officer
Charles A. Bancroft CFO, EVP & Head-Global Business Operations
Paul von Autenried Chief Information Officer & Senior Vice President
Thomas James Lynch Chief Scientific Officer & Executive VP
Vicki L. Sato Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON16.70%362 930
NOVARTIS11.20%225 262
ROCHE HOLDING LTD.4.56%220 102
PFIZER9.45%211 109
MERCK AND COMPANY12.38%179 869